DFW Continues Firm Growth with New Business Development Hire

DFW Capital Partners (“DFW”) announced today that it has hired Peter Conzola as Vice President, Business Development. In this role, Peter will oversee deal origination and sourcing activities at the firm. Prior to joining DFW, Peter served as Vice President, Head of Business Development at SFW Capital Partners where he led the firm’s sourcing activities.… Read more »

Accounting Firms Unite to Create ‘Sorren,’ a New Top 50 Firm

[Meridian, Idaho] – May 1, 2025 – The newly branded Sorren, a Top 50 accounting firm, was established by a collection of like-minded firms from across the country with the desire to create one firm and a shared purpose. The collection of firms, long connected through the BDO Alliance and industry relationships, have now formalized… Read more »

Sebela Announces Positive Results from Phase 3 TRIUMpH Program

Tegoprazan proves to be faster acting and more effective than a proton pump inhibitor (PPI) in the healing of erosive esophagitis (EE). Met all primary and secondary endpoints in healing phase of EE. Demonstrated superiority over lansoprazole, a PPI, in healing at weeks 2 and 8 in all grades of EE. Tegoprazan met all primary… Read more »

Saol Therapeutics Announces Major Clinical Milestones

SL1009 targets a 2025 FDA decision for Pyruvate Dehydrogenase Complex Deficiency (PDCD), while SL1002 advances toward Phase III trials for osteoarthritis knee pain and spasticity ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, April 17, 2025 /PRNewswire/ — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced multiple updates on its rapidly advancing clinical development portfolio. SL1009, Sodium Dichloroacetate (DCA)DCA is an… Read more »

Voiant Acquires Voxeleron to Expand with AI Technology

April 15, 2025 – Voiant, a leader in clinical trial imaging solutions, today is announcing the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant advancement in Voiant’s mission to accelerate the development of innovative treatments for eye diseases. Voiant’s extensive ophthalmic clinical trial expertise coupled with… Read more »

FIECON Joins Herspiegel to Expand Commercialization Services

YARDLEY, Pa. and LONDON, April 7, 2025 /PRNewswire/ — Herspiegel, a world leader in pharmaceutical and biotech commercialization services, continues its strategic expansion by joining forces with FIECON, Europe’s leading health economics and market access consultancy firm. This strategic integration expands Herspiegel’s proven market access capabilities and enhances Herspiegel’s global footprint. The integrated global access services will support patient access… Read more »

AQUALIS Acquires Stormwater Compliance Solutions, LLC

MORRISVILLE, N.C.- AQUALIS, the nation’s leading provider of sustainable water management, engineering and compliance services for critical infrastructure, announced today it has acquired the assets of Stormwater Compliance Solutions, LLC (SCS). Headquartered in Chester, N.J. with a second office in the Greater Denver area, Stormwater Compliance Solutions has been performing stormwater inspections, maintenance and compliance… Read more »

DFW Named a Top 50 PE Firm for Executives For Third Year

CLEVELAND, OH. – March 12, 2025   PrivateEquityCXO and Falcon Partners have announced 2025’s Top 50 Private Equity Firms who best enable their portfolio company executives to drive maximum returns. Winners are determined through data collected from thousands of sponsor-backed executives highlighting their experiences and rating funds using PE-CXO’s Nine Dimensions of Governance Fit®, a… Read more »

FDA Approves MUDELLA®, from Sebela Women’s Health Inc.

FDA Approves MIUDELLA®, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years, from Sebela Women’s Health Inc. ROSWELL, GA, February 24, 2025 – Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA® (copper intrauterine system) for… Read more »

Saol Therapeutics announces acceptance of New Drug Application

ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, Jan. 28, 2025 — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SL1009, Sodium Dichloroacetate Oral Solution (DCA).  DCA will be used with a proprietary genetic test to treat an orphan pediatric mitochondrial disease, Pyruvate… Read more »